Saladax Biomedical Closes $8 Million Series C Financing

Saladax Biomedical, Inc., a Bethlehem, PA-based company which develops novel diagnostic tests for the practical delivery of personalized medicine, closed its $8.4m Series C financing led by Excel Venture Management of Boston.
Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors.
The company’s products span all stages of development and address a variety of therapeutic areas, with an initial focus in oncology.
The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

Join the discussion